Status:
UNKNOWN
Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborating Sponsors:
Hebei Medical University Fourth Hospital
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Esophageal Neoplasms
Eligibility:
All Genders
18-69 years
Phase:
PHASE3
Brief Summary
This phase III trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for esophageal carcinoma with limited ...
Eligibility Criteria
Inclusion
- Age\<70
- Diagnosis of clinical stage T2-4N0-1M1（According to UICC 2002）
- A untreated squamous esophageal carcinoma
- Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3
- Adequate organ function
- No known history of drug allergy
- Blood routine examination : WBC≥4.0
- hepatic and renal function are normal
Exclusion
- Age≥ 70 or \< 18
- Already received the treatment of chemotherapy or radiotherapy
- Pregnant or lactating females
- Known drug allergy
- Without agreement of informed consent form
- Insufficient hepatorenal function or Blood routine examination
- Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental disorders, uncontrolled severe infection, active ulceration which need intervention.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2021
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT03308552
Start Date
December 1 2017
End Date
August 30 2021
Last Update
January 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, Beijing Municipality, China, 100021